A systematic review of the safety information contained within the Summaries of Product Characteristics of medications licensed in the United Kingdom for Attention Deficit Hyperactivity Disorder. how does the safety prescribing advice compare with national guidance?

Research

Nicola Savill^* and Chris J Bushe

Child and Adolescent Psychiatry and Mental Health 2012, 6:2 doi:10.1186/1753-2000-6-2

No comments have yet been made on this article.